The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness

Pharmacogenetics

Volumn 8, Issue 3, 1998, Pages 259-268

  Steen, Vidar M ^a   Løvlie, Roger ^a   Osher, Yamima ^b   Belmaker, Robert H ^b   Berle, Jan Ø ^a   Gulbrandsen, Anne Karin ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bipolar disorder; DNA polymorphisms; INPP1 gene; Prediction of lithium response

Indexed keywords

COMPLEMENTARY DNA; LITHIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BIPOLAR DISORDER; FEMALE; FORECASTING; GENE FREQUENCY; HUMANS; ISRAEL; JEWS; LITHIUM; MALE; MIDDLE AGED; NORWAY; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES; PILOT PROJECTS; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TRANQUILIZING AGENTS;

EID: 0031776806     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol 1971; 233:267-268.
2. Allison JH, Blisner ME, Holland WH, Hipps PP, Sherman WR. Increased brain myo-inositol 1-phosphate in lithium-treated rats. Biochem Biophys Res Commun 1976; 71:664-670.
3. Atack JR, Broughton HB, Pollack SJ. Inositol monophosphatase - a putative target for Li+ in the treatment of bipolar disorder. Trends Neurosci 1995; 18:343-349.
4. Atack JR. Inositol monophosphatase, the putative therapeutic target for lithium. Brain Res Brain Res Rev 1996; 22:183-190.
5. Avissar S, Schreiber G. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders. Biol Psychiatry 1992; 31:435-459.
6. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982; 206:587-595.
7. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59:411-419.
8. Bohus M, Forstner U, Kiefer C, Gebicke Harter P, Timmer J, Spraul G, et al. Increased sensitivity of the inositol-phospholipid system in neutrophils from patients with acute major depressive episodes. Psychiatry Res 1996; 65:45-51.
9. Brown AS, Mallinger AG, Renbaum LC. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania. Am J Psychiatry 1993; 150:1252-1254.
10. Baastrup PC, Schou M. Lithium as a prophylactic agent. Arch Gen Psychiatry 1967; 16:162-172.
11. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 14:349-352.
12. Casebolt TL, Jope RS. Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biol Psychiatry 1989; 25:329-340.
13. Dixon JF, Lee CH, Los GV, Hokin LE. Lithium enhances accumulation of [3H]inositol radioactivity and mass of second messenger inositol, 1,4,5-trisphosphate in monkey cerebral cortex slices. J Neurochem 1992; 59:2332-2335.
14. Dixon JF, Los GV, Hokin LE. Lithium stimulates glutamate 'release' and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc Natl Acad Sci USA 1994; 91:8358-8362.
15. Dixon JF, Hokin LE. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc Natl Acad Sci USA 1997;94:4757-4760.
16. 2+ response in neutrophils from patients under chronic lithium therapy. Eur Arch Psychiatry Clin Neurosci 1994; 243:240-243.
17. Gee NS, Ragan CI, Watling KJ, Aspley S, Jackson RG, Reid GG, et al. The purification and properties of myo-inositol monophosphatase from bovine brain. Biochem J 1988; 249:883-889.
18. Gershon S, Soares JC. Current therapeutic profile of lithium. Arch Gen Psychiatry 1997; 54:16-20.
19. Goodwin FK, Jamison KR. Manic-depressive illness. New York; Oxford University Press: 1990.
20. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980; 255:10896-10901.
21. Hirvonen MR, Savolainen K. Lithium-induced decrease of brain inositol and increase of brain inositol-1-phosphate is transient. Neurochem Res 1991; 16:905-911.
22. Honchar MP, Ackermann KE, Sherman WR. Chronically administered lithium alters neither myo-inositol monophosphatase activity nor phosphoinositide levels in rat brain. J Neurochem 1989; 53:590-594.
23. Inhorn RC, Majerus PW. Properties of inositol polyphosphate 1-phosphatase. J Biol Chem 1988; 263:14559-14565.
24. Ishima Y, Fujimagari M, Masuzawa Y, Waku K. Inositol 1,4,5-trisphosphate accumulation in brain of lithium-treated rats. Lipids 1993; 28:577-581.
25. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, Warsh JJ. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J Neurochem 1996; 66:2402-2409.
26. Kennedy ED, Challiss RA, Nahorski SR. Lithium reduces the accumulation of inositol polyphosphate second messengers following cholinergic stimulation of cerebral cortex slices. J Neurochem 1989; 53:1652-1655.
27. Kennedy ED, Challiss RA, Ragan CI, Nahorski SR. Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochem J 1990; 267:781-786.
28. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93:8455-8459.
29. Lenox RH, Manji HK, Lithium. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. New York: American Psychiatric Press; 1995. pp. 303-349.
30. Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 13:23-31.
31. Lovlie R, Eiken HG. Increased 32P-SSCP sensitivity by combining RE digestion and extended X-ray film exposures. BioTechniques 1997; 22:598-602.
32. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52:531-543.
33. Poli F, Cattaneo R, Crespiatico L, Nocco A, Sirchia G. A rapid and simple method for reversing the inhibitory effect of heparin on PCR for HLA class II typing. PCR Methods Appl 1993; 2:356-358.
34. Schon M, Juel-Nielsen N, Strömgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17:250-260.
35. Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE. Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat. J Neurochem 1981; 36:1947-51.
36. Silverstone PH, Hanstock CC, Fabian J, Staab R, Allen PS. Chronic lithium does not alter human myo-inositol or phosphomonoester concentrations as measured by 1H and 31P MRS. Biol Psychiatry 1996; 40:235-246.
37. Steen VM, Gulbrandsen AK, Eiken HG, Berle JO. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics 1996; 6:113-116.
38. Varney MA, Godfrey PP, Drummond AH, Watson SP. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells. Mol Pharmacol 1992; 42:671-678.
39. York JD, Veile RA, Donis Keller H, Majerus PW. Cloning, heterologous expression, and chromosomal localization of human inositol polyphosphate 1-phosphatase. Proc Natl Acad Sci USA 1993; 90:5833-5837.
40. York JD, Ponder JW, Majerus PW. Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA 1995; 92:5149-5153.